RA CAPITAL MANAGEMENT, L.P. - 08 Nov 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
TYRA
Transactions as of
08 Nov 2024
Net transactions value
+$19,836,066
Form type
4
Filing time
13 Nov 2024, 17:00:07 UTC
Previous filing
30 Oct 2024
Next filing
25 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Purchase $19,836,066 +1,220,681 +16% $16.25 8,697,956 08 Nov 2024 See footnotes F1, F2
holding TYRA Common Stock 1,496,613 08 Nov 2024 See footnotes F2, F3
holding TYRA Common Stock 442,721 08 Nov 2024 See footnotes F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 These securities are held directly by the Nexus Fund.
F4 These securities are held directly by the Account.

Remarks:

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.